(Q30400508)

English

Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

21 June 2017

Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study (English)

1 reference

Europe PubMed Central

21 June 2017

0 references

1 reference

based on heuristic

inferred from title

influenza vaccine

1 reference

based on heuristic

inferred from title

1

object named as

Cem Gabay

1 reference

Europe PubMed Central

21 June 2017

Claire-Anne Siegrist

12

object named as

Claire-Anne Siegrist

1 reference

Europe PubMed Central

21 June 2017

Jakob R. Passweg

1 reference

ORCID Public Data File 2021

author name string

Michael Bel

2

1 reference

Europe PubMed Central

21 June 2017

Christophe Combescure

3

1 reference

Europe PubMed Central

21 June 2017

Camillo Ribi

4

1 reference

Europe PubMed Central

21 June 2017

Sara Meier

5

1 reference

Europe PubMed Central

21 June 2017

Klara Posfay-Barbe

6

1 reference

Europe PubMed Central

21 June 2017

Stéphane Grillet

7

1 reference

Europe PubMed Central

21 June 2017

Jörg D Seebach

8

1 reference

Europe PubMed Central

21 June 2017

Laurent Kaiser

9

1 reference

Europe PubMed Central

21 June 2017

Werner Wunderli

10

1 reference

Europe PubMed Central

21 June 2017

Pierre-André Guerne

11

1 reference

Europe PubMed Central

21 June 2017

H1N1 Study Group

13

1 reference

Europe PubMed Central

21 June 2017

publication date

1 June 2011

1 reference

Europe PubMed Central

21 June 2017

Arthritis & Rheumatology

1 reference

Europe PubMed Central

21 June 2017

63

1 reference

Europe PubMed Central

21 June 2017

6

1 reference

Europe PubMed Central

21 June 2017

1486-1496

1 reference

Europe PubMed Central

21 June 2017

Risk factors and prognostic influence of infection in a single cohort of 87 adults with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1002%2FART.30325

21 January 2018

Prevention and treatment of influenza in immunocompromised patients

1 reference

https://api.crossref.org/works/10.1002%2FART.30325

21 January 2018

Influenza immunization in systemic lupus eruthematosus. A double-blind trial

1 reference

https://api.crossref.org/works/10.1002%2FART.30325

21 January 2018

Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis. Safety and immunogenicity.

1 reference

https://api.crossref.org/works/10.1002%2FART.30325

21 January 2018

Influenza vaccination of patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).

1 reference

https://api.crossref.org/works/10.1002%2FART.30325

21 January 2018

Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.

1 reference

https://api.crossref.org/works/10.1002%2FART.30325

21 January 2018

Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults.

1 reference

https://api.crossref.org/works/10.1002%2FART.30325

21 January 2018

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.30325

21 January 2018

The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy

1 reference

https://api.crossref.org/works/10.1002%2FART.30325

21 January 2018

The 1982 revised criteria for the classification of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1002%2FART.30325

21 January 2018

Nomenclature of systemic vasculitides. Proposal of an international consensus conference

1 reference

https://api.crossref.org/works/10.1002%2FART.30325

21 January 2018

Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study.

1 reference

https://api.crossref.org/works/10.1002%2FART.30325

21 January 2018

Measurement of patient outcome in arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.30325

21 January 2018

Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.

1 reference

https://api.crossref.org/works/10.1002%2FART.30325

21 January 2018

Maintenance of serological memory by polyclonal activation of human memory B cells.

1 reference

https://api.crossref.org/works/10.1002%2FART.30325

21 January 2018

Vaccination and autoimmune disease: what is the evidence?

1 reference

https://api.crossref.org/works/10.1002%2FART.30325

21 January 2018

Are anti-infectious vaccinations safe and effective in patients with autoimmunity?

1 reference

https://api.crossref.org/works/10.1002%2FART.30325

21 January 2018

Vaccinations in patients with immune-mediated inflammatory diseases

1 reference

https://api.crossref.org/works/10.1002%2FART.30325

21 January 2018

Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease

1 reference

https://api.crossref.org/works/10.1002%2FART.30325

21 January 2018

Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers

1 reference

https://api.crossref.org/works/10.1002%2FART.30325

21 January 2018

The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1002%2FART.30325

21 January 2018

Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab

1 reference

https://api.crossref.org/works/10.1002%2FART.30325

21 January 2018

The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination

1 reference

https://api.crossref.org/works/10.1002%2FART.30325

21 January 2018

Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response

1 reference

https://api.crossref.org/works/10.1002%2FART.30325

21 January 2018

AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age.

1 reference

https://api.crossref.org/works/10.1002%2FART.30325

21 January 2018

Paradoxical response to a novel influenza virus vaccine strain: the effect of prior immunization

1 reference

https://api.crossref.org/works/10.1002%2FART.30325

21 January 2018

Epidemiologic and immunologic significance of age distribution of antibody to antigenic variants of influenza virus

1 reference

https://api.crossref.org/works/10.1002%2FART.30325

21 January 2018

Effect of a second, booster, influenza vaccination on antibody responses in quiescent systemic lupus erythematosus: an open, prospective, controlled study

1 reference

https://api.crossref.org/works/10.1002%2FART.30325

21 January 2018

Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials.

1 reference

https://api.crossref.org/works/10.1002%2FART.30325

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FART.30325

21 January 2018

Identifiers

10.1002/ART.30325

1 reference

Europe PubMed Central

21 June 2017

1 reference

Europe PubMed Central

21 June 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30400508&oldid=1577175357"